Subscriber Content Read Preview
Eli Lilly is nearing a settlement with federal prosecutors over alleged improper marketing of the antipsychotic drug Zyprexa.
Subscriber Content Read Preview
Glaxo's internal emails indicate the company's own data was reflecting a study, which linked its diabetes treatment Avandia to heart-attack risk.
Subscriber Content Read Preview
Elan is seeking new funds and has launched a strategic review that could lead to a merger or the sale of the Irish drug maker.
Subscriber Content Read Preview
Pfizer is laying off up to 800 researchers as the pharmaceutical industry faces pressure to cut spending.
Subscriber Content Read Preview
Bristol-Myers will team with ZymoGenetics to develop a hepatitis C treatment, in a deal that could bring ZymoGenetics more than $1 billion.
Subscriber Content Read Preview
Subscriber Content Read Preview
Subscriber Content Read Preview
Subscriber Content Read Preview
View an interactive map that shows you how stocks in the Pharmaceuticals & Biotech sector are doing today, at a glance.
Get in-depth research on Pharmaceuticals & Biotech companies, including complete news and financials, earnings estimates and more.
Search recent Pharmaceuticals & Biotech articles for the following word(s):
Show all Pharmaceuticals & Biotech articlesAsk a question about anything you choose, and let readers from the Journal Community answer it.
Hello
Your question to the Journal Community Your comments on articles will show your real name and not a username.Why?
Create a Journal Community profile to avoid this message in the future. (As a member you agree to use your real name when participating in the Journal Community)